

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



富景農業

Fujing Holdings Co., Limited
富景中國控股有限公司

(the “Company”)

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2497)

CHANGE OF DIRECTORS
AND
CHANGE IN COMPOSITION OF BOARD COMMITTEES

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director**”) of Fujing Holdings Co., Limited (the “**Company**”) announces that Ms. Chow Wai Mee May (“**Ms. Chow**”) has tendered her resignation as an independent non-executive Director, a member of each of Audit Committee (the “**Audit Committee**”) and Nomination Committee (the “**Nomination Committee**”) and chairperson of Remuneration Committee of the Company (the “**Remuneration Committee**”) with effect from 16 January 2025 due to her decision to devote more time to her other social works commitments.

Ms. Chow has confirmed that she has no disagreement with the Board and that there are no matters in relation to her resignation that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to take this opportunity to express its gratitude and appreciation to Ms. Chow contribution to the Company during her tenure of office.

APPOINTMENT OF DIRECTORS

The Board further announces that with effect from 16 January 2025:

- (i) Ms. Geng Juan (“**Ms. Geng**”) has been appointed as an executive Director and a member of the Nomination Committee; and
- (ii) Dr. Wang Wenyuan (“**Dr. Wang**”) has been appointed as an independent non-executive Director, a member of each of the Audit Committee and the Nomination Committee and chairperson of the Remuneration Committee.

Biographical Details of Ms. Geng

Ms. Geng, aged 41, holds a Bachelor Diploma in Pharmacy from Jiangxi University of Traditional Chinese Medicine. Currently, she is the Chief Human Officer at Qingdao Fujing Agriculture Development Company Limited, an indirect wholly-owned subsidiary of the Company, responsible for developing and overseeing human resource strategies, ensuring effective communication channels, and establishing incentive mechanisms within the company. Previously, Ms. Geng was the General Manager at Qingdao Fujing Investment Company Limited from September 2013 to June 2024, where she managed overall operations and financial management. Additionally, she worked as the General Manager at Laixi Dongfang Mingzhu Stone Processing Co., Limited from August 2004 to June 2024, also overseeing comprehensive operational and financial duties. Ms. Geng is cohabiting with Mr. Zhang Yonggang, the chairman of the Board, chief executive officer, executive Director and controlling shareholder of the Company, as his spouse. Ms. Geng is the sister of Ms. Geng Qi, a substantial shareholder of the Company.

Save as disclosed above, as at the date of this announcement, Ms. Geng (i) does not hold any other positions with the Company or other members of the Group; (ii) does not, nor did she in the past three years, hold any directorships in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas; (iii) does not have any relationships with any Directors, senior management or substantial shareholders or controlling shareholders (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”)) of the Company; and (iv) does not have any interests in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

Ms. Geng has entered into a service agreement with the Company for a term of five years which is subject to retirement and re-election at the annual general meeting of the Company. Ms. Geng is entitled to a director’s fee of RMB6,000 per month which was determined by the Board based on the recommendation of the Remuneration Committee of the Company, taking into account her duties, responsibilities and prevailing market conditions. Ms. Geng’s remuneration will be reviewed periodically by the Remuneration Committee and the Board.

Save as disclosed above, as confirmed by Ms. Geng, there is no further information to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the appointment of Ms. Geng that need to be brought to the attention of the shareholders of the Company.

Biographical Details of Dr. Wang

Dr. Wang, aged 42, holds a Doctor of Philosophy in Industrial Engineering and Logistics Management from The Hong Kong University of Science and Technology. He has published multiple papers and received various awards for his contributions to environmental leadership and innovation management. Currently, he serves as the Secretary-General of the Global Inno-tech Industrialisation Society (GIIS) and is the Founder and Managing Director of Globtech Crossborder (Hong Kong) Limited, mainly responsible for designing business strategies to enter Chinese market for the world-leading innovations and technologies, and leading ongoing strategic planning, partnership development, business development and negotiations in China. Dr. Wang has held significant roles, including General Manager for China at Saietta Group plc, where he led strategic planning and market entry initiatives for a leading e-motor company. He was also the Vice President and Head of China Office at YASA Limited, facilitating partnerships with major automotive OEMs and local governments. His earlier experience includes working as a Senior Consultant at Oxford University Innovation, the technology transfer office of the University of Oxford, where he secured substantial projects and funding for international technology transfer and commercialisation, and as General Manager of a joint venture company.

Save as disclosed above, as at the date of this announcement, Dr. Wang (i) does not hold any other positions with the Company or other members of the Group; (ii) does not, nor did he in the past three years, hold any directorships in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas; (iii) does not have any relationships with any Directors, senior management or substantial shareholders or controlling shareholders (as defined in Listing Rules) of the Company; and (iv) does not have any interests in the shares or underlying shares of the Company within the meaning of the SFO.

Dr. Wang has confirmed (i) his independence as regards each of the factors referred to in Rule 3.13(1) to (8) of the Listing Rules; (ii) that he has no past or present financial or other interest in the business of the Group or any connection with any core connected person (as defined in the Listing Rules) of the Company; and (iii) that there is no other factors that may affect his independence at the time of his appointment.

Dr. Wang has entered into an appointment letter for a term of two years with the Company. He is subject to retirement and will be eligible for re-election at the annual general meeting of the Company pursuant to the Memorandum and Articles of Association of the Company. The director's fee for Dr. Wang, as specified in his appointment letter, is HK\$120,000 per annum. This amount was determined by the Board based on the recommendation

of the Remuneration Committee, taking into account his duties, responsibilities and prevailing market conditions. Dr. Wang's remuneration will be reviewed periodically by the Remuneration Committee and the Board.

Save as disclosed above, as confirmed by Dr. Wang, there is no further information to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the appointment of Dr. Wang that need to be brought to the attention of the shareholders of the Company.

The Board would like to extend a warm welcome to Ms. Geng and Dr. Wang for joining the Board.

CHANGE IN COMPOSITION OF BOARD COMMITTEES

With effect from 16 January 2025, the composition of the Board committees will be changed as follows:

- (1) Ms. Chow resigns as the chairperson of the Remuneration Committee and a member of each of the Audit Committee and the Nomination Committee;
- (2) Ms. Geng has been appointed as a member of the Nomination Committee; and
- (3) Dr. Wang has been appointed as the chairperson of the Remuneration Committee and a member of each of the Audit Committee and the Nomination Committee.

By order of the Board
Fujing Holdings Co., Limited
Zhang Yonggang
*Chairman, Chief Executive Officer and
Executive Director*

Hong Kong, 16 January 2025

As at the date of this announcement, the Board comprises Mr. Zhang Yonggang (Chairman and Chief Executive Officer), Mr. Lyu Zhonghua, Mr. Cui Wei, Mr. Pang Jinhong and Ms. Geng Juan as executive Directors; and Mr. Lam Chik Tong, Dr. Li Junliang and Dr. Wang Wenyuan as independent non-executive Directors.